學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
CanniMed Therapeutics: Acquiror or Target?
內容大綱
On November 14, 2017, Aurora Cannabis Inc. (Aurora) made a proposal to CanniMed Therapeutics Inc. (CanniMed) to acquire all of CanniMed's issued and outstanding common shares in a share exchange that valued CanniMed's common shares at a premium of almost 30 per cent over the previous day's share price. In its proposal, Aurora requested a response from CanniMed's board of directors by November 17, 2018, in the absence of which it intended to launch a formal, hostile takeover bid. Instead of responding to Aurora's offer, CanniMed's board of directors issued a news release advising shareholders to take no action regarding Aurora's bid and announcing that CanniMed had entered into an agreement to wholly acquire Newstrike Resources Inc. (Newstrike). As a result, Aurora took its bid directly to CanniMed shareholders, with a condition that CanniMed terminate the proposed Newstrike acquisition. Now CanniMed investors had to carefully consider their alternatives: should they tender their shares to Aurora's bid, or should they hold on to their shares according to the CanniMed board's recommendation and then decide whether to vote in favour of the Newstrike transaction?